Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
HOME > BUSINESS
BUSINESS
- [Data] Sales of Nippon Shinyaku’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Zeria’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Kissei’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Fuso's Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of ASKA's Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Nippon Chemiphar's Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Wakamoto's Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Torii’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- Regulatory Challenges Remain for Introduction of Combination Vaccines: MSD VP Shirasawa
December 12, 2012
- Fycompa Approved for Use under NHS Scotland: Eisai
December 12, 2012
- Santen to Set Up Demand-Chain Strategic Planning Office
December 12, 2012
- Astellas, UMN Complete Administration of Seasonal Vaccine to Participants in Domestic PIII Trial
December 12, 2012
- Meta-Analysis of Study Data Finds 39% Overall Response Rate with Velcade Retreatment: Takeda
December 12, 2012
- Hisamitsu, Asahi Kasei Pharma to Comarket OAB Transdermal Drug
December 11, 2012
- Mochida Revving Up Collaboration Efforts in Biosimilars
December 11, 2012
- Otsuka Pharmaceutical Factory to Establish Infusion Products Subsidiary in India
December 11, 2012
- Ethical Drug Sales Up 6.1% in October: Crecon Report
December 11, 2012
- Feburic’s Market Share to Exceed 50% in Near Future: Teijin President Ohyagi
December 11, 2012
- Mylan Applies for Ciclosporin for Additional Indication Based on Data from Public Domain
December 11, 2012
- Teva Pharma Halts Sales of Pinatos Due to GMP Non-Compliance of South Korean Supplier
December 10, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…